Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development)

0 avg rating
( 0 ratings by Goodreads )
 
9781617375347: Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development)
View all copies of this ISBN edition:
 
 

Leading researchers, from the Novartis group that pioneered Gleevec/Glivec™ and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing protein kinase inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors.

"synopsis" may belong to another edition of this title.

From the Back Cover:

Protein kinases function as components of signal transduction pathways, playing a central role in the control of cell growth, metabolism, differentiation, and apoptosis. The development of selective protein tyrosine kinase (PTK) inhibitors that can block or modulate diseases, such as cancer, with abnormalities in these signaling pathways is considered a promising approach for drug development. Currently, more than 20 different PTKs are being considered as potential therapeutic targets in oncology. In Protein Tyrosine Kinases: From Inhibitors to Useful Drugs, leading researchers from the Novartis group that pioneered Gleevec/Glivec™ and from around the world comprehensively survey the state-of-the-art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made toward generating "selective" low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing PTK inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining "on-target" vs "off-target" effects of kinase inhibitors.
Authoritative and state-of-the-art, Protein Tyrosine Kinases: From Inhibitors to Useful Drugs details the key stages in the design of PTK inhibitors and their development into useful drugs.

"About this title" may belong to another edition of this title.

Buy New View Book
List Price: US$ 279.99
US$ 254.71

Convert currency

Shipping: FREE
From United Kingdom to U.S.A.

Destination, rates & speeds

Add to Basket

Other Popular Editions of the Same Title

9781588293848: Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development)

Featured Edition

ISBN 10:  158829384X ISBN 13:  9781588293848
Publisher: Humana Press, 2005
Hardcover

Top Search Results from the AbeBooks Marketplace

1.

Published by Humana Press Inc., United States (2010)
ISBN 10: 1617375349 ISBN 13: 9781617375347
New Paperback Quantity Available: 10
Seller:
Book Depository hard to find
(London, United Kingdom)
Rating
[?]

Book Description Humana Press Inc., United States, 2010. Paperback. Condition: New. Language: English . This book usually ship within 10-15 business days and we will endeavor to dispatch orders quicker than this where possible. Brand New Book. Leading researchers, from the Novartis group that pioneered Gleevec/Glivec (TM) and around the world, comprehensively survey the state of the art in the drug discovery processes (bio- and chemoinformatics, structural biology, profiling, generation of resistance, etc.) aimed at generating PTK inhibitors for the treatment of various diseases, including cancer. Highlights include a discussion of the rationale and the progress made towards generating selective low molecular-weight kinase inhibitors; an analysis of the normal function, role in disease, and application of platelet-derived growth factor antagonists; and a summary of the factors involved in successful structure-based drug design. Additional chapters address the advantages and disadvantages of in vivo preclinical models for testing protein kinase inhibitors with antitumor activity and the utility of different methods in the drug discovery and development process for determining on-target vs off-target effects of kinase inhibitors. Softcover reprint of hardcover 1st ed. 2006. Seller Inventory # LIE9781617375347

More information about this seller | Contact this seller

Buy New
US$ 254.71
Convert currency

Add to Basket

Shipping: FREE
From United Kingdom to U.S.A.
Destination, rates & speeds

2.

DORIANO FABBRO
Published by Humana Press (2010)
ISBN 10: 1617375349 ISBN 13: 9781617375347
New Paperback Quantity Available: 1
Seller:
Herb Tandree Philosophy Books
(Stroud, GLOS, United Kingdom)
Rating
[?]

Book Description Humana Press, 2010. Paperback. Condition: NEW. 9781617375347 This listing is a new book, a title currently in-print which we order directly and immediately from the publisher. For all enquiries, please contact Herb Tandree Philosophy Books directly - customer service is our primary goal. Seller Inventory # HTANDREE0308972

More information about this seller | Contact this seller

Buy New
US$ 249.72
Convert currency

Add to Basket

Shipping: US$ 10.35
From United Kingdom to U.S.A.
Destination, rates & speeds

3.

Published by Humana Press (2010)
ISBN 10: 1617375349 ISBN 13: 9781617375347
New Softcover Quantity Available: 15
Print on Demand
Seller:
Rating
[?]

Book Description Humana Press, 2010. Condition: New. This item is printed on demand for shipment within 3 working days. Seller Inventory # LP9781617375347

More information about this seller | Contact this seller

Buy New
US$ 283.71
Convert currency

Add to Basket

Shipping: US$ 3.43
From Germany to U.S.A.
Destination, rates & speeds

4.

Published by Humana Press (2010)
ISBN 10: 1617375349 ISBN 13: 9781617375347
New Paperback Quantity Available: 1
Seller:
Revaluation Books
(Exeter, United Kingdom)
Rating
[?]

Book Description Humana Press, 2010. Paperback. Condition: Brand New. reprint edition. 304 pages. 9.02x5.98x0.72 inches. In Stock. Seller Inventory # zk1617375349

More information about this seller | Contact this seller

Buy New
US$ 382.16
Convert currency

Add to Basket

Shipping: US$ 9.72
From United Kingdom to U.S.A.
Destination, rates & speeds

5.

Published by Humana Press (2010)
ISBN 10: 1617375349 ISBN 13: 9781617375347
New Softcover Quantity Available: 1
Seller:
Irish Booksellers
(Portland, ME, U.S.A.)
Rating
[?]

Book Description Humana Press, 2010. Condition: New. book. Seller Inventory # M1617375349

More information about this seller | Contact this seller

Buy New
US$ 445.76
Convert currency

Add to Basket

Shipping: US$ 3.27
Within U.S.A.
Destination, rates & speeds

6.

Humana Press
Published by Humana Press (2010)
ISBN 10: 1617375349 ISBN 13: 9781617375347
New Paperback Quantity Available: 1
Seller:
Books Express
(Portsmouth, NH, U.S.A.)
Rating
[?]

Book Description Humana Press, 2010. Paperback. Condition: New. Ships with Tracking Number! INTERNATIONAL WORLDWIDE Shipping available. Buy with confidence, excellent customer service! Softcover reprint of hardcover 1st ed. 2006. Seller Inventory # 1617375349n

More information about this seller | Contact this seller

Buy New
US$ 459.08
Convert currency

Add to Basket

Shipping: FREE
Within U.S.A.
Destination, rates & speeds